Short answer
BALCHEM CORP (BCPC) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Balchem reported fiscal Q2 2026 earnings for the quarter ended June 30, 2026.
BALCHEM CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Balchem reported fiscal Q2 2026 earnings for the quarter ended June 30, 2026
- Full financial results and management commentary contained in Exhibit 99.1
- Earnings release furnished under Regulation FD, not treated as filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 record results: sales $284.0M, up 11.2%; GAAP EPS $1.39, up from $1.17
- Adjusted EBITDA $77.9M, up 12.6%, with gross margin broadly stable at 36.5% versus 36.4%
- All segments grew: Human Nutrition sales $176.9M, Animal Nutrition $64.5M, Specialty Products $40.5M
- Credit amendment extends maturity to July 24, 2031 and raises borrowing capacity from $550M to $650M
- Capital returns remained significant: $28.8M quarterly repurchases and $114M over trailing twelve months, despite $88.8M net debt
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BALCHEM CORP 8-K filings
Get the next BCPC 8-K as it lands
Follow BCPC for push alerts, or ask the research agent what this filing means.